Savara (SVRA) Times Interest Earned (2011 - 2026)
Savara (SVRA) posted quarterly Times Interest Earned of -$63.19 for Q1 2026, down 194.46% year-over-year from $66.9 in Q1 2025, and down 547.96% quarter-over-quarter from $14.11 in Q4 2025.
Savara (SVRA) Times Interest Earned (2011 - 2026) Analysis & Trends
Savara (SVRA) has reported Times Interest Earned for 16 consecutive years, with -$63.19 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 194.46% year-over-year to -$63.19; the TTM figure through Mar 2026 stood at -$1719.3 (down 4470.85% YoY), while the FY2025 annual figure was -$0.87, up 9.95% from the prior year.
- Times Interest Earned fell to -$63.19 in Q1 2026 per SVRA's latest filing, from $14.11 in the prior quarter.
- Across five years, Times Interest Earned topped out at $14.11 in Q4 2025 and bottomed at -$982.5 in Q2 2025.
- Historically, Times Interest Earned has averaged -$96.23 across 5 years, with a median of -$30.93 in 2023.
- On a YoY basis, Times Interest Earned climbed as much as 122.85% in 2025 and fell as far as 1209.15% in 2025.
- Savara's Times Interest Earned stood at -$25.41 in 2022, then slipped by 29.45% to -$32.89 in 2023, then plunged by 87.68% to -$61.73 in 2024, then surged by 122.85% to $14.11 in 2025, then plunged by 547.96% to -$63.19 in 2026.
- Business Quant data shows SVRA's Times Interest Earned at -$63.19 in Q1 2026, $14.11 in Q4 2025, and -$982.5 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -28.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.15 |
| Mar 31, 2026 | -63.19 |
| Dec 31, 2025 | 14.11 |
| Jun 30, 2025 | -982.50 |
| Mar 31, 2025 | -21.46 |
| Dec 31, 2024 | -61.73 |
| Sep 30, 2024 | -93.80 |
| Jun 30, 2024 | -75.05 |
| Mar 31, 2024 | -41.93 |
| Dec 31, 2023 | -32.89 |
| Sep 30, 2023 | -45.80 |
| Jun 30, 2023 | -28.96 |
| Mar 31, 2023 | -26.10 |
| Dec 31, 2022 | -25.41 |
| Sep 30, 2022 | -20.82 |
| Jun 30, 2022 | -17.54 |
| Mar 31, 2022 | -16.62 |
| Dec 31, 2021 | -21.28 |
| Sep 30, 2021 | -100.73 |
| Jun 30, 2021 | -92.50 |